DuoDopa ved Parkinsons Sykdom
Sist oppdatert: Sist revidert:
Sist revidert av:Unn Ljøstad
- Olanow CW1, Kieburtz K2, Odin P3, Espay AJ4, Standaert DG5, Fernandez HH6, Vanagunas A7, Othman AA8, Widnell KL9, Robieson WZ10, Pritchett Y11, Chatamra K10, Benesh J10, Lenz RA9, Antonini A12; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014; Feb;13(2):141-9. pmid:24361112 PubMed
- Antonini A, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015 Mar;21(3):231-5 . pmid:25585993 PubMed
- Rus T, Premzl M, Križnar NZ, Kramberger MG, Rajnar R, Ocepek L, Pirtošek Z, Trošt M. Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study. Acta Neurol Scand. 2022 Nov;146(5):537-544. doi: 10.1111/ane.13675. Epub 2022 Jul 28. PMID: 35903042 PubMed
- Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry 2015; 86: 490-495. pmid:25168395 PubMed
- Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano . Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2015 Oct 25 . pmid:26498913 PubMed
- Unn Ljøstad, spesialist i nevrologi, professor PhD
- Åse Mygland, spesialist i nevrologi, professor dr med